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While studying respiratory infections in Peru, we identified 
Venezuelan equine encephalitis virus (VEEV) in a nasopha-
ryngeal swab, indicating that this alphavirus can be pres-
ent in human respiratory secretions. Because VEEV may 
be infectious when aerosolized, our finding is relevant for 
the management of VEEV-infected patients and for VEEV 
transmission studies.
Venezuelan equine encephalitis virus (VEEV) is one of many alphaviruses transmitted through 
the bite of infected mosquitoes (1,2). VEEV primarily 
infects equine species, causing severe encephalitis and 
death. VEEV may also infect humans, causing fever and 
influenza-like symptoms that include headache, chills, 
myalgia, nausea, and vomiting. In severe cases, human 
VEEV infection may result in neurologic complications 
that lead to fatalities. Acute VEEV infection is usually 
confirmed by PCR, sequencing from blood (3), or 
both, or in the case of encephalitis, from spinal fluid. 
Nasopharyngeal swabs are rarely tested for alphaviruses 
like VEEV because they are considered nontraditional 
sample types for these kinds of pathogens.
The US Naval Medical Research Unit No. 6, in 
coordination with the local ministry of health, conducts 
routine surveillance for respiratory and febrile pathogens 
under Institutional Review Board–approved protocols that 
comply with all applicable federal regulations governing 
the protection of human subjects. As part of these efforts, 
nasopharyngeal swabs and serum samples are tested for 
a variety of possible etiologies. Frequently, however, a 
particular sample fails to yield a recognized etiology. This 
result happens in several scenarios: a patient is infected 
with an unknown pathogen or with a pathogen for which 
there is no known diagnostic; a known pathogen has 
mutated and changed such that a known diagnostic is no 
longer effective; or a pathogen is present at a concentration 
too low to diagnose. In these cases, it may be possible to 
identify the potential etiology using approaches that can 
identify novel or divergent pathogens, like unbiased next-
generation sequencing (NGS).
In 2013, in Iquitos, Peru, we identified a 16-year-
old boy who reported a variety of undifferentiated ill-
ness symptoms, including fever, chills, general malaise, 
myalgia, headache, rhinorrhea, sore throat, nausea, 
vomiting, abdominal pain, retroorbital pain, rash, and 
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photophobia. A field-administered rapid test for influ-
enza on a nasopharyngeal swab specimen was negative. 
More thorough laboratory tests, including a highly mul-
tiplexed MassTag PCR assay that can detect >20 viral 
and bacterial pathogens (4), were also negative (Fig-
ure, panel A). The sample entered a pathogen discovery 
pipeline routinely used to amplify and identify unknown 
etiologies (5). In brief, we cultured 200 µL of the origi-
nal nasopharyngeal sample in Vero-E6, LLCMK2, and 
MDCK cells. Cytopathic effect appeared by day 4 in 
Vero-E6 and LLCKM2 cells and by day 19 in MDCK 
cells. We used culture supernatant from day 4 LLCMK2 
cells as starting material for NGS MiSeq libraries, which 
we prepared, sequenced, and processed as described (5). 
Sequencing generated 704,444 raw reads, from which 
28,555 were de novo assembled into a single 11,412-nt 
contig (Figure B). When blasted, the contig matched the 
complete genome of a VEEV-ID strain isolated in Peru 
from 1994 (GenBank accession no. KC344526.1) with 
99% identity. 
Given the health implications of detecting live al-
phaviruses in human respiratory secretions, we sought 
to confirm the finding by retesting the original nasopha-
ryngeal swab, and by examining available paired serum 
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Figure. Testing for respiratory 
pathogens in a 16-year-old 
boy in Iquitos, Peru. A) Testing 
algorithm showing the types of 
samples collected during both 
acute- and convalescent-phase 
periods, the tests performed 
on each, and the results (in 
parentheses). B) Depth of 
coverage plot and schematic 
representation of the isolated 
VEEV genome, including all 
genes (nsP1, nsP2, nsP3, nsP4, 
C, E3, E2, 6K, and E1), drawn 
to approximate scale. Genomic 
information for this isolate has 
been deposited in GenBank 
(accession no. MF590066). 
Flu, influenza virus; IIF, indirect 
immunofluorescence; NGS, 
next-generation sequencing; 
VEEV, Venezuelan equine 
encephalitis virus.
samples collected during acute and convalescent peri-
ods. All confirmatory tests we conducted (3) were posi-
tive for VEEV: the original swab and the acute serum 
sample tested positive for VEEV by reverse transcription 
PCR and confirmatory Sanger sequencing; the acute-
phase serum sample enabled isolation of VEEV; and the 
convalescent-phase serum sample showed a 1:1,600 rise 
in IgM titer, indicating the patient had seroconverted. 
Subsequent inspection of the associated metadata also 
indicated the sample had been collected at a time when 
VEEV circulated in the region.
Febrile surveillance studies have shown that VEEV 
is prevalent in many countries throughout Latin America 
(3,6). Although respiratory symptoms have been reported 
in association with VEEV infection (7) and there is >1 
report of VEEV in throat swabs (8), human respiratory 
secretions are seldom tested for alphaviruses. In fact, 
the presence of VEEV in respiratory secretions, as well 
as its implications for health and biosafety, are rarely 
discussed. Although person-to-person transmission 
of VEEV has not been documented, VEEV can be 
infectious through aerosolized particles (9,10), so the 
potential for an alternate transmission route exists. 
This possibility should be considered both during indi-
vidual management of VEEV-infected patients and in 
studies considering VEEV transmission dynamics or 
prevention strategies.
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